Protein Is Identified As An Antigen, E.g., Immunogenic Carriers, Etc. Patents (Class 530/403)
-
Publication number: 20040038319Abstract: The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention.Type: ApplicationFiled: August 20, 2002Publication date: February 26, 2004Inventors: Rudolf H. Aebersold, Patricia Q. Bottari, Michael H. Gelb, Frantisek Turecek
-
Publication number: 20040023846Abstract: Stable protein conformational isomers and methods for producing and isolating such isomers are disclosed. Methods of using such isomers, and products and compositions comprising such isomers are also disclosed.Type: ApplicationFiled: August 1, 2002Publication date: February 5, 2004Inventor: Rowen J.Y. Chang
-
Patent number: 6673347Abstract: Protein and polypeptide derivatives and their salts are claimed characterized in that a protein or polypeptide is conjugated via an intermediate grouping containing at least one radical of the formula —C(R)═N— (or —N═C(R)—) or —CH(R)—NH— (or —NH—CH(R)—), wherein R is hydrogen or a hydrocarbon residue which may be substituted, with the same or a different protein or polypeptide, with a reporter group or a cytotoxic agent as well as a process for their preparation and the novel intermediates therefor.Type: GrantFiled: May 12, 1994Date of Patent: January 6, 2004Assignee: Gryphon TherapeuticsInventors: Robin Ewart Offord, Keith Rose
-
Patent number: 6673580Abstract: The invention provides for methods of modifying immunodominant epitopes on polypeptides, preferably polypeptides intended for therapeutic use. Knowledge of immunodominant epitopes prior to clinical use of polypeptides would be useful to design and engineer less immunogenic molecules. The invention provides for methods of identifying immunodominant epitopes and modifying an immunodominant epitope to reduce the immune response to the polypeptide while still retaining a substantial therapeutic activity of the polypeptide. The modified polypeptides are useful therapeutically.Type: GrantFiled: June 1, 2001Date of Patent: January 6, 2004Assignee: Genentech, Inc.Inventors: Eugen Koren, John Hok Nin Lowe
-
Patent number: 6673905Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.Type: GrantFiled: August 1, 2001Date of Patent: January 6, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Vince Pozsgay
-
Publication number: 20030232742Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.Type: ApplicationFiled: November 9, 2001Publication date: December 18, 2003Inventors: Stefan Peters, Dietmar Leipert, Christian Eickmeier, John Edward Park, Martin Lenter, Pilar Garin-Chesa, Juergen Mack
-
Patent number: 6664370Abstract: Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.Type: GrantFiled: July 15, 1999Date of Patent: December 16, 2003Assignee: University of WashingtonInventors: Martin A. Cheever, Mary L. Disis
-
Patent number: 6663869Abstract: A homogeneous polyoxime composition is provided, in which the polyoxime molecules present comprise a first organic baseplate molecule, which is a polypeptide, wherein the baseplate molecule is linked to at least two second organic molecules, which may be the same or different from one another. In the compositions, the linkages between the baseplate and said organic molecules are oxime linkages formed by reaction of an orthogonal reactive group on each the organic molecules with a complementary orthogonal reactive group on the baseplate.Type: GrantFiled: August 4, 2000Date of Patent: December 16, 2003Assignee: Gryphon Therapeutics, Inc.Inventors: Keith Rose, Robin E. Offord
-
Patent number: 6660271Abstract: Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical epitopes at specified locations.Type: GrantFiled: September 26, 2001Date of Patent: December 9, 2003Assignee: Proteinix CompanyInventors: John H. Kenten, Alfonso Tramontano, Aprile L. Pilon, Gerald L. Lohnas, Steven F. Roberts
-
Patent number: 6660525Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.Type: GrantFiled: February 10, 2000Date of Patent: December 9, 2003Assignee: Alza CorporationInventors: Francis J. Martin, Samuel Zalipsky, Shi Kun Huang
-
Patent number: 6656472Abstract: Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbonhydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inparts enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae which may be serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F), or Neisseria meningitidis, which may be serotype (A, B, C) W-135 or Y. Such oligosaccharide fragments may be sized from about 2 to about 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeY or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule.Type: GrantFiled: December 22, 2000Date of Patent: December 2, 2003Assignee: Aventis Pasteur LimitedInventors: Pele Chong, Alf Lindberg, Michel H. Klein
-
Patent number: 6649591Abstract: In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression.Type: GrantFiled: October 1, 1999Date of Patent: November 18, 2003Assignee: Medinox, Inc.Inventor: Ching-San Lai
-
Patent number: 6635744Abstract: The invention provides fibroblast growth factor homologous factor (FHF) polypeptides and nucleic acid molecules that encode them. Also included in the invention are diagnostic and therapeutic methods using FHF polypeptides and nucleic acids.Type: GrantFiled: January 25, 2000Date of Patent: October 21, 2003Assignee: The Johns Hopkins University School of MedicineInventors: Jeremy Nathans, Philip M. Smallwood
-
Patent number: 6635745Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.Type: GrantFiled: January 9, 2001Date of Patent: October 21, 2003Assignee: Novartis AGInventors: Richard Sedrani, Valérie Quesniaux Ryffel
-
Patent number: 6632437Abstract: The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.Type: GrantFiled: November 15, 1993Date of Patent: October 14, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, John B. Robbins, J. N. Sarvamangala Devi
-
Patent number: 6632615Abstract: The invention concerns a method for isolating a target biological material contained in a sample, which consists in providing a capture phase comprising an organic molecule having at least a reactive function and at least a protein material capable of recognizing or binding, specifically and directly or indirectly, with the target biological material, said protein material having a specific covalent binding site with the organic molecule reactive function, consisting of at least a tag comprising at least six contiguous lysine, or lysine derivative residues, the method consists in contacting said target biological material with at least the capture phase; and detecting the target biological material fixed on the capture phase: The invention also concerns the capture and detection phases, and a reagent containing them.Type: GrantFiled: April 21, 1999Date of Patent: October 14, 2003Assignee: Bio MerieuxInventors: Francois Mallet, Thierry DeLair, Catherine Ladaviere, Armelle Novelli-Rousseau, Marie-Helene Charles
-
Patent number: 6630350Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.Type: GrantFiled: September 3, 1999Date of Patent: October 7, 2003Assignee: Roche Diagnostics GmbHInventors: Christa Hubner-Parajsz, Hartmut Schetters, Rosemarie Kientsch-Engel, Thomas Meier, Martin Kaufmann, Andreas Gallusser, Rolf Deeg
-
Patent number: 6627202Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV cote antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.Type: GrantFiled: June 4, 2001Date of Patent: September 30, 2003Assignee: Biogen, Inc.Inventor: Kenneth Murray
-
Patent number: 6610659Abstract: The use of cognate heat shock protein 70-peptide complex to elicit an immune response against cancer and viral, bacterial and other infectious agents.Type: GrantFiled: December 6, 1999Date of Patent: August 26, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventor: Srivastava K. Pramod
-
Patent number: 6605285Abstract: This invention relates to a process for the preparation of Salmonella vaccine by treating entrotoxin and cytotoxins with formalin and adding immuno-potentiator selected from Freund's complete adjuvant (FCA) or Vitamin E or Saponin to said concentrated toxoids to get the desired vaccine. The present invention also provides a Salmonella vaccine for protection against Salmonellosis in poultry.Type: GrantFiled: March 19, 2001Date of Patent: August 12, 2003Assignee: G.B. Pant University of Agriculture & TechnologyInventors: Vishwashwar Dutt Sharma, Subodh Kumar, Shri Krishna Garg, Ram Sagar Mishra, Tarani Kanta Barman
-
Patent number: 6602989Abstract: The detection of gallium in biological samples is required due to its role in the diagnosis of tumor and for possible treatment of malignancies. However, the use of purely instrumental techniques is unsuitable for detection of low levels of gallium in biological matrices. New protein conjugates have been synthesized based on 4-(2-pyridylazo) ligands. The conjugates detect gallium in biological matrices using a non antibody-based sandwich assay format. The recovery level is between 97-101.3 with a relative standard deviation of less than 5%. The assay results in a detection limit of 5×10−8 M and a remarkable selectivity for gallium(III) relative to other metals investigated. The new method provides adequate accuracy for gallium applicable for animal physiology and clinical toxicology.Type: GrantFiled: May 17, 2000Date of Patent: August 5, 2003Assignee: The Research Foundation of State University of New YorkInventors: Omowunmi A. Sadik, Hongwu Xu
-
Publication number: 20030143236Abstract: The present invention relates to novel forms and configurations of intercellular adhesion molecule (ICAM) including multimeric configurations that effectively bind to human rhinovirus and can effectively reduce HRV infectivity. When in a multimeric configuration, preferably as dimers, these proteins display enhanced binding of HRV and are able to reduce HRV infectivity as well as the infectivity of other viruses known to bind to the “major” group human rhinovirus receptor (HRR). The multimerized proteins may also be used to block tICAM interaction with lymphocyte function-associated antigen-1 (LFA-1).Type: ApplicationFiled: June 5, 1995Publication date: July 31, 2003Inventors: JEFFREY M. GREVE, ALAN MCCLELLAND
-
Patent number: 6592872Abstract: The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of Bacillus anthracis and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.Type: GrantFiled: September 15, 1997Date of Patent: July 15, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kurt Klimpel, Theresa J. Goletz, Naveen Arora, Stephen H. Leppla, Jay A. Berzofsky
-
Patent number: 6589532Abstract: The invention relates to DNA coding for a peptide of a papilloma virus major capsid protein or a papilloma virus genome. The invention also relates to proteins coded by the papilloma virus genome and antibodies directed against said proteins, in addition to the use thereof in diagnosis, therapy and vaccination.Type: GrantFiled: June 12, 2001Date of Patent: July 8, 2003Assignee: Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Ethel-Michele De Villiers-Zur Hausen, Harald Zur Hausen
-
Publication number: 20030125527Abstract: Compounds and methods are provided for a single-step covalent attachment of a label to a molecule comprising forming a covalently attachable labeling reagent for alkylating the molecule. Then, combining the covalently attachable labeling reagent with a mixture containing the molecule, under conditions wherein the labeling reagent has reactivity with the molecule thereby forming a covalent bond.Type: ApplicationFiled: January 23, 2001Publication date: July 3, 2003Inventors: Jon A. Wolff, James E. Hagstrom, Paul Michael Slattum, Vladimir Budker
-
Patent number: 6586392Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: March 22, 2001Date of Patent: July 1, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Michael R. Boyd
-
Patent number: 6582700Abstract: The present invention concerns a synthetic construct comprising a linear core chain having two or more side chains pending directly from different points on the linear core chain. Each of the side chains comprises an epitopic site of an antigen or a peptide. The synthetic constructs are monomeric units that can be linked together or polymerized to form a polymer. In this embodiment the epitopic sites of the side chains may be the same or different. The linear core chain may be a linear sequence of amino acids having two or more of the same peptide pending directly from different points on the linear sequence. Another aspect of the present invention concerns a support having one or more of the above synthetic constructs or polymers coupled thereto. Another embodiment of the present invention is directed to antibodies raised against the above synthetic constructs or polymers. The antibodies can be purified using the above mentioned supports.Type: GrantFiled: November 13, 1998Date of Patent: June 24, 2003Assignee: Medical University of South CarolinaInventor: Christian Schwabe
-
Patent number: 6576244Abstract: This invention provides methods of inducing a protective or therapeutic immune response to Helicobacter infection in a mammal by parenterally administering to the mammal one or more Helicobacter antigens and an adjuvant selected from one or more of LT, CT, LTB, and CTB.Type: GrantFiled: June 18, 1999Date of Patent: June 10, 2003Assignee: Acambis, Inc.Inventors: Richard A. Weltzin, Bruno Guy
-
Patent number: 6572860Abstract: Peptide constructs chemically synthesized to contain a Herpes Simplex Virus specific antigenic peptide, such as, the 322-332 peptide (H1) from the ICP27 protein of Herpes Simplex Virus (HSV-1) and a peptide from a T cell binding ligand (TCBL), such as &bgr;-2M (aa 35-50), which elicits a TH1-like response in vitro tests in mice, were protective against challenge with HSV.Type: GrantFiled: March 30, 2000Date of Patent: June 3, 2003Assignee: CEL-SCI CorporationInventors: Daniel H. Zimmerman, Kenneth S. Rosenthal
-
Patent number: 6566500Abstract: The present invention provides methods to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS). The invention also provides ITs and cytokines which have been mutated to lack amino acid sequences which induce VLS. Also disclosed are methods for producing peptides that inhibit the induction of VLS by ITs and cytokines. Also disclosed are peptides comprising the (x)D(y) sequence to promote the extravasation of other molecules. Toxins mutated in the (x)D(y) motif or active site residues are disclosed for used in vaccines.Type: GrantFiled: March 30, 2000Date of Patent: May 20, 2003Assignee: Board of Regents, The University of Texas SystemInventors: Ellen S. Vitetta, Victor F. Ghetie, Joan Smallshaw, Roxana G. Baluna
-
Patent number: 6562597Abstract: This invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein. Moreover, this invention deals with a papilloma virus genome containing such a DNA. Furthermore, this invention concerns proteins coded by the papilloma virus genome and virus-like particles as well as antibodies directed thereagainst and the use thereof for diagnosis, treatment and vaccination.Type: GrantFiled: January 23, 2002Date of Patent: May 13, 2003Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Vladimir Shamanin, Ethel-Michele De Villiers-Zur Hausen, Harald Zur Hausen
-
Publication number: 20030087322Abstract: Analytical reagents and mass spectrometry-based methods using these reagents for the rapid, and quantitative analysis of proteins or protein function in mixtures of proteins. The methods employ affinity labeled protein reactive reagents having three portions: an affinity label (A) covalently linked to a protein reactive group (PRG) through a linker group (L). The linker may be differentially isotopically labeled, e.g., by substitution of one or more atoms in the linker with a stable isotope thereof. These reagents allow for the selective isolation of peptide fragments or the products of reaction with a given protein (e.g., products of enzymatic reaction) from complex mixtures. The isolated peptide fragments or reaction products are characteristic of the presence of a protein or the presence of a protein function in those mixtures. Isolated peptides or reaction products are characterized by mass spectrometric (MS) techniques.Type: ApplicationFiled: April 20, 2001Publication date: May 8, 2003Applicant: University of WashingtonInventors: Rudolf Hans Aebersold, Michael H. Gelb, Steven P. Gygi, C. Ronald Scott, Frantisek Turecek, Scott A. Gerber, Beate Rist
-
Patent number: 6558671Abstract: Cysteine-depleted CTL epitopes can elicit a stronger or more specific CTL response than the native, cysteine-containing CTL epitope of a disease associated antigen.Type: GrantFiled: September 20, 1999Date of Patent: May 6, 2003Assignee: The University of Virginia Patent FoundationInventors: Craig L. Slingluff, Donald F. Hunt, Victor H. Engelhard, David Kittlesen
-
Patent number: 6555345Abstract: This invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein. Moreover, this invention deals with a papilloma virus genome containing such a DNA. Furthermore, this invention concerns proteins coded by the papilloma virus genome and virus-like particles as well as antibodies directed thereagainst and the use thereof for diagnosis, treatment and vaccination.Type: GrantFiled: January 23, 2002Date of Patent: April 29, 2003Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Vladimir Shamanin, Ethel-Michele De Villiers-Zur Hausen, Harald Zur Hausen
-
Patent number: 6548066Abstract: The invention concerns immunogens, immunogenic compositions and method for the treatment of gastrin-dependent tumors. The immunogens comprise a peptide from the CCK-B/gastrin-receptor conjugated to a spacer and to an immunogenic carrier. The immunogens are capable of inducing antibodies in vivo which bind to the CCK-B/gastrin-receptor in tumor cells, thereby preventing growth stimulating peptide hormones from binding to the receptors, and inhibiting tumor cell growth. The immunogens also comprise antibodies against the CCK-B/gastrin-receptor for passive immunization. The invention also concerns diagnostic methods for detecting gastrin-dependent tumors in vivo or from a tissue biopsy using the antibodies of the invention.Type: GrantFiled: May 12, 1998Date of Patent: April 15, 2003Assignee: Aphton CorporationInventors: Dov Michaeli, Martyn Caplin, Susan A. Watson, Stephen Grimes
-
Patent number: 6541606Abstract: This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition.Type: GrantFiled: August 10, 1999Date of Patent: April 1, 2003Assignee: Altus Biologics Inc.Inventors: Alexey L. Margolin, Nazar K. Khalaf, Nancy L. St. Clair, Scott L. Rakestraw, Bhami C. Shenoy
-
Publication number: 20030050469Abstract: The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.Type: ApplicationFiled: October 9, 2002Publication date: March 13, 2003Applicant: Stressgen Biotechnologies Corporation, a Victoria, Canada corporationInventors: Marvin Siegel, N. Randall Chu, Lee A. Mizzen
-
Publication number: 20030036110Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.Type: ApplicationFiled: July 6, 2001Publication date: February 20, 2003Applicant: INNOGENETICS N.V.Inventors: Geert Maertens, Fons Bosman, Guy De Martynoff, Marie-Ange Buyse
-
Patent number: 6521234Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.Type: GrantFiled: October 16, 2000Date of Patent: February 18, 2003Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney
-
Publication number: 20030026807Abstract: The invention is directed to improved immunopotentiating systems for preparation of immunogenic materials. More particularly, the invention is directed to immunogenic compositions containing a protein, polypeptide, or peptide, a hydrophobic anchor, and a proteosome. The immunogenic compositions are suitable for use as therapeutic agents and vaccines.Type: ApplicationFiled: December 2, 1997Publication date: February 6, 2003Inventor: GEORGE H. LOWELL
-
Patent number: 6506885Abstract: Hybridoma cell lines have been generated which produce and secrete monoclonal antibodies which selectively bind to tilmicosin. These hybridomas may be obtained by using as an immunization agent or immunogen, 23-deoxo-23-demycinosyl tilmicosin which has been conjugated to an immunogenic carrier. The antibodies may be used to detect and/or quantify tilmicosin in biological samples. The monoclonal antibodies also may be incorporated into kits.Type: GrantFiled: September 27, 2001Date of Patent: January 14, 2003Assignee: The United States of America as represented by the Secretary of AgricultureInventor: Ross C. Beier
-
Publication number: 20030004320Abstract: Novel activated peptides and conjugates thereof, useful in diagnostic assays and therapeutics, and processes for the preparation thereof are disclosed.Type: ApplicationFiled: September 2, 1999Publication date: January 2, 2003Inventors: MICHAEL E. ANNUNZIATO, PAUL S. PALUMBO
-
Publication number: 20020198364Abstract: The invention is directed to contraceptive vaccines comprising a carrier protein or fragment thereof in peptide linkage with a reproduction related polypeptide, protein or fragment thereof, and to DNAs encoding the chimeric proteins. The invention also includes the use of the chimeric proteins in immunocontraceptive methods.Type: ApplicationFiled: March 14, 2000Publication date: December 26, 2002Inventors: Jerry J. Reeves, Kevin P. Bertrand, Yuzhi Zhang
-
Publication number: 20020192723Abstract: A 28 kD antigen present in the intracellular signal transduction oncogene and an immunoassay method for diagnosing Systemic Lupus Erythematosis using the 28 kD antigen as a target substance for detecting target binding substance in biological fluid from an animal or human having symptoms of Systemic Lupus Erythematosis.Type: ApplicationFiled: February 25, 2000Publication date: December 19, 2002Inventor: Tai June Yoo
-
Patent number: 6488935Abstract: The present invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein and a papilloma virus genome, respectively. Furthermore, the present invention concerns proteins coded by the papilloma virus genome and antibodies directed thereagainst as well as the use thereof for diagnosis, treatment and vaccination.Type: GrantFiled: May 26, 2000Date of Patent: December 3, 2002Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Ethel-Michelle De Villiers Zur Hausen, Harald Zur Hausen
-
Patent number: 6475489Abstract: The present invention relates to synthesis of HBsAg in yeast. Yeast expression vectors comprising a yeast promoter, ADH1, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HBsAg by yeast has been achieved. The product is antigenic (reactive with anti-HBsAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBSAg synthesized by yeast has identical sedimentation behavior to purified, naturally-occurring HBsAq particles purified from Alexander cells as measured by sucrose gradient sedimentation.Type: GrantFiled: June 7, 1995Date of Patent: November 5, 2002Assignee: The Regents of the University of CaliforniaInventors: William J. Rutter, Pablo D. T. Valenzuela, Benjamin D. Hall, Gustav Ammerer
-
Patent number: 6472506Abstract: The invention relates to a polysaccharide-peptide conjugate wherein the polysaccharide is advantageously immunogenic, which comprises a polysaccharide chain composed of repeat units and a plurality of peptide moieties, each moiety containing a cysteine residue and being covalently attached at random along the polysaccharide chain, through an indirect bond being achieved through either a linker or a spacer-linker moiety provided that the spacer entity of the spacer-linker moiety is linked to the amino, hydroxyl or carboxyl group of the polysaccharide. To this end a useful linker may be, e.g., N-(&ggr;-maleimidobutyrloxy)succinimide ester. Such a conjugate may typically exhibit a “Rake” configuration. Conjugation processes are also disclosed. Conjugates of the invention are in particular useful in the vaccinal field to elicit a protective long term immune response against a pathogenic microorganism from which the Immunogenic polysaccharide is derived.Type: GrantFiled: November 4, 1998Date of Patent: October 29, 2002Assignee: Aventis Pasteur S.A.Inventors: Monique Moreau, Noëlle Mistretta
-
Patent number: 6469139Abstract: The present invention relates to modified human chorionic gonadotropin (&bgr;-hCG) proteins and their medical use as immunological contragestatives. The modification causes a reduction in the cross-reactivity of the modified &bgr;-hCG protein with luteinizing hormone (LH) as defined by the ability of both proteins to react with the same antibody.Type: GrantFiled: May 13, 1998Date of Patent: October 22, 2002Assignee: University College LondonInventors: Ivan Maurice Roitt, Peter John Delves, Torben Lund
-
Patent number: 6465259Abstract: A method for quantitatively and/or qualitatively assaying an analyte in a sample, wherein the analyte is a receptor binding compound, has low detection limits equivalent to those of radioreceptor assays. The method comprises the steps of a) contacting the sample with material comprising a receptor for the analyte in order for receptor-analyte binding to occur and b) further contacting the sample with a detectable ligand for the receptor in order for receptor-ligand binding to occur, followed by c) separating the resulting receptor bound and free fractions, d) subjecting the receptor bound fraction to dissociating conditions releasing the ligand from the receptor and e) assaying for the dissociated ligand in a manner known per se for the detection of the detectable ligand.Type: GrantFiled: May 6, 1999Date of Patent: October 15, 2002Assignee: Merska B.V.Inventors: Maria Johanna Janssen, Kornelis Ensing, Rokus Arie De Zeeuw
-
Patent number: 6458359Abstract: A chimeric polypeptide encoded by the chimeric gene formed by the DNA sequences that encode the antigenic determinants of four proteins of L. infantum is disclosed. The protein obtained, rLiPO-Ct-Q (pPQI) has a molecular mass of 38 kD with an isoelectric point of 7.37. This chimeric polypeptide is useful for preventing and/or treating leishmaniosis in animals or humans.Type: GrantFiled: December 23, 1999Date of Patent: October 1, 2002Assignee: C.B.F. Leti S.A.Inventors: Carlos Alonso Bedate, Jose Maria Requena Rolania, Manuel Soto Alvarez